



Preparation of chemotherapy treatments.
Credit: Science Photo Library

Editorial

- 87** Authors: beware of the elephant traps!
P Wiffen

Systematic review

- 88** Quality assurance standards and their use in the preparation of parenteral systemic anticancer therapy products in healthcare establishments: a scoping review
K D Murphy, C O' Mahony, M McCarthy, M M Saab, T M Barbosa, A Fleming, P Cotter, B Noonan, E Breen, G Carroll, A De Frein, P Heckmann, M Triggs, L Sahn

Original research

- 94** Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients
Y Qin, Z Chen, S Gao, Y Shen, Y Ye
- 101** Development and implementation of medication-related clinical rules for obstetrics, gynaecology, and paediatric outpatients
Q Chen, L Wang, M Lin, W Chen, W Wu, Y Chen
- 107** Classification of non-antineoplastic intravenously administered drugs according to their toxicity risk: the path towards safe drug administration
T Giménez Poderós, J J Fernández Cabero, M Valero Domínguez

- 111** Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy
S Kemps, M Soleyman, H Huls, M Labots, M Crul

- 117** Reducing the use of sleep-inducing drugs during hospitalisation by a multi-faceted intervention: a pilot study
S Heinemann, J Klemperer, E Hummers, R Nau, W Himmel

- 124** Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments
E Tejedor-Tejada, D Rubio Calvo, A García Andreo

- 127** Factors associated with potential drug–drug interactions in psychiatric inpatients
A Ranković, I Milentijevic, S Jankovic

- 135** Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials
M Abdel-Tawab, M Waßmuth, F Gegenfurtner, A Hawe, J H Schefe, A M Strunz, J Wübert

- 143** Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study
D Young, F Cummings, S Latter

- 150** Real-world effectiveness and durability of dual antiretroviral therapy in HIV-infected patients
L Pérez-Cordón, A Sánchez, S Marin, L Force, M Serra-Prat, E Palomera, L Campins

- 156** Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years
A Romagnoli, F Santoleri, A Costantini, A Di Risio

EAHP position paper

- 162** Clinical trials
P Polidori, D Makridaki, S Kohl, delegates of the 52nd EAHP General Assembly

Case report

- 165** Rare case report of moxifloxacin-induced persistent hiccups
J Zhou, F Wang, S Li

Short reports

- 168** Factors influencing accuracy when preparing injectable drug concentrations in appliance with clinical practice: a norepinephrine case study
S Gilliot, A Marin Mena, S Genay, M Masse, M Thibaut, N Carta, D Lannoy, L Négrier, C Barthélémy, B Décaudin, P Odou
- 171** Development of a quality assessment tool for pharmacy and therapeutics committees and subsequent pilot testing
N Schönenberger, C Meyer-Massetti, S Bravo

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available under the BMJ Journals open access scheme. See <https://authors.bmj.com/open-access>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org

recycle
When you have finished with this magazine please recycle it.

- 175** Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series
C Guzmán Cordero, M Saez-Torres de Vicente

PostScript

- 178** Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'
X X Zhou, H J Ji
- 179** Off-label use of cardiovascular drugs as an indicator of therapeutic need in paediatrics
S M Cammarata, G Capone

- 179** In-hospital expenditure for medical devices in relation to funds from diagnosis-related groups and ambulatory activity: temporal trend from 2019 to 2022
A Messori, S Trippoli, C Marinai

- 180** Concomitant drug use of nirmatrelvir/ritonavir and CYP3A4-modulating antimicrobial agents: an approach for drug use
R Visscher, N Yalçın, I Bayraktar, A Bayraktar-Ekincioglu

- 183** Interprofessional collaborative practice is strong in young health professionals: evidence from an Italian Winter School attended by hospital pharmacists and internal medicine physicians
L Camuffo, D Mengato, A Nobili, P Santalucia, M Proietti, F Venturini